Anti-PD-1 | Nano Publications

2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Although treatment with high-dose (HD) radiation (XRT) and NBTXR3 on primary tumors in combination with systemic anti-PD1 was able to significantly improve abscopal effect in 344SQR murine metastatic lung cancer model, most of the mice eventually died due to the growth of secondary tumors. […]

2020 – SITC – NBTXR3 From Bench to Bedside

Clinical Data NBTXR3, Congress Abstracts, In Vitro in Vivo NBTXR3

Despite recent advances, resistance to immune checkpoint inhibitors (ICI), observed in over 80% of treated patients, is currently the main challenge immuno-oncology is facing. Intense efforts are being made to identify combination therapies that could improve ICI response rates. Administered intratumorally, NBTXR3 enhances the energy dose deposited by ionizing radiation within tumor cells, increasing the anti-tumor efficacy of radiation therapy (XRT) without adding toxicity to surrounding tissues. […]

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Most cancer patients present resistance to immune therapy; only approximately 15% of patients respond to immune checkpoint inhibitors (ICI). Strategies able to increase ICI response are thus of great interest. Radiotherapy (RT), by acting as an immunomodulator is a good candidate to increase the proportion of ICI responders. However, RT dose and ultimate efficacy are limited by potential toxicity to healthy tissues. NBTXR3, a first in class radioenhancer administered by intratumoral injection, has been designed at the nanoscale to increase RT energy dose deposition within the tumor. […]

2019 – ESMO IO – NBTXR3 with anti-PD-1

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

The majority of cancer patients are resistant to immune therapy; only around 15% respond to immune checkpoint inhibitors (ICI). Thus, strategies able to increase ICI response are of great interest. Recent work suggests radiotherapy (RT) can act as an immunomodulator to increase the proportion of ICI responders and improve clinical outcomes. However, RT dose and ultimate efficacy are limited by toxicity related to exposure of healthy tissues. […]

2019 – RSNA – Anti-tumor immune response induced by NBTXR3

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

First in class hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy (RT) increase radiation dose deposit within cancer cells compared to RT alone. Given that RT can prime an anti-tumor immune response we hypothesized that this response could be enhanced by NBTXR3+RT in both animals and humans. […]

2019 – ASTRO – NBTXR3 generates an anti tumor immune response

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy (RT) increase radiation dose deposit within cancer cells compared to RT alone. Currently 7 clinical trials are underway to evaluate NBTXR3+RT. To date, no dose limiting toxicities (DLTs) have been observed. Given that RT can prime an anti-tumor immune response we hypothesized that this response could be enhanced by NBTXR3+RT in both animals and humans. […]

2019 – ASCO – NBTXR3 induces antitumor immune response

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) can prime an anti-tumor immune response. Unfortunately, this response rarely generates total tumor destruction and abscopal effect. When activated by RT, intratumorally (IT) administered hafnium oxide nanoparticles (NBTXR3) locally increase radiation dose deposit and tumor cell death compared to RT alone. We hypothesized that NBTXR3 + RT could enhance the anti-tumor immune response, both in mice and humans. […]

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Preoperative radiotherapy (RT) is an option for a subset of patients with locally advanced primary or relapsed tumors. Yet, its impact on efficacy in terms of pathological response is limited, highlighting the need for novel multimodal therapies aimed at local control with low toxicity. NBTXR3 is made of hafnium oxide nanoparticles which, injected intratumorally (IT) and activated by ionizing radiation, yield a tumor-localized high energy deposit and increase cell death compared to the same dose of RT alone. […]

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Lung

Despite proven efficacy, a limited number of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or metastatic non-small cell lung cancer (NSCLC) benefit from anti-PD-1 treatment. Indeed, most pts do not respond to initial therapy due to intrinsic re-sistance to checkpoint inhibition. There is thus an important unmet medical need for a curative treatment in these pts and converting the local immune microenvironment to a “hot” phenotype may help to overcome therapeutic resistance. […]